Evidence map›Paper›PMID 39605973›Full record

ArticleBrain communications2024

Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders.

Bárbara Fernandes Gomes, Atul Kumar, Nicholas J Ashton, Sara Hall, Erik Stomrud, Ruben Smith, Henrik Zetterberg, Kaj Blennow, Niklas Mattsson-Carlgren, Oskar Hansson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Novel blood-based proteomic signatures across multiple neurodegenerative diseases.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bárbara Fernandes GomesDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 43180 Mölndal, Sweden.ORCID https://orcid.org/0000-0002-1512-6699
Atul KumarDepartment of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, 20213 Malmö, Sweden.ORCID https://orcid.org/0000-0002-2166-4805
Nicholas J AshtonDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 43180 Mölndal, Sweden.
Sara HallDepartment of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, 20213 Malmö, Sweden.ORCID https://orcid.org/0000-0001-6585-9105
Erik StomrudDepartment of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, 20213 Malmö, Sweden.
Ruben SmithDepartment of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, 20213 Malmö, Sweden.ORCID https://orcid.org/0000-0001-7147-0112
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 43180 Mölndal, Sweden.ORCID https://orcid.org/0000-0003-3930-4354
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 43180 Mölndal, Sweden.
Niklas Mattsson-CarlgrenDepartment of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, 20213 Malmö, Sweden.ORCID https://orcid.org/0000-0002-8885-7724
Oskar HanssonDepartment of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, 20213 Malmö, Sweden.ORCID https://orcid.org/0000-0001-8467-7286

Funding

Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI HEATHER Allyson BIMONTE-NELSON · 2021 to 2026
$24.9M
NIA NIH HHS P30 AG072980
6 · The paper itself

Abstract

Disease-specific fluid biomarkers are in demand for parkinsonian syndromes (PS). Corticotropin-releasing hormone (CRH) was proposed as a biomarker for Lewy body disease. As such, this project aimed to confirm CRH as a potential biomarker for different PS. CRH and misfolded α-synuclein (αSyn) were measured in CSF. The primary cohort included Lewy body disease patients (i.e. Parkinson's disease or dementia with Lewy bodies,

Indexed as

atypical parkinsonismdementia with Lewy bodiesfluid biomarkerParkinson’s diseasesynucleinopathy

Identifiers

PMID39605973
PMCPMC11601160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.